01
Overview
- Develops RNA-based biomarkers for precision oncology[1][4]
- Focuses on drug response prediction through tumor microenvironment analysis[2][4]
- Commercialized HistoPlusSM: Lung Cancer test via LabCorp partnership[5][6]
- Therapeutic areas
- Oncology
- Modalities
- RNA-based diagnosticsCompanion diagnostics
- Industry
- Molecular Diagnostics
02
Drug pipeline
1 assetPurIST
Commercial- Indications
- Pancreatic cancer
03
Partnerships
Laboratory Corporation of America Holdings (LabCorp)Pharmaceutical/biotechnology companies (undisclosed per sources)
Beyond the preview
Go deeper on GeneCentric Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneCentric Therapeutics.
Explore the full profile